Paul Schaefer

6.4k total citations · 1 hit paper
97 papers, 4.7k citations indexed

About

Paul Schaefer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Paul Schaefer has authored 97 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Epidemiology. Recurrent topics in Paul Schaefer's work include Colorectal Cancer Treatments and Studies (12 papers), Glioma Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (10 papers). Paul Schaefer is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Glioma Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (10 papers). Paul Schaefer collaborates with scholars based in United States, Canada and United Kingdom. Paul Schaefer's co-authors include Jan C. Buckner, Jeff A. Sloan, Al B. Benson, Charles L. Loprinzi, Judith R. OʼFallon, Richard M. Goldberg, C. David James, Roy E. Ritzmann, Robert B. Jenkins and Paul J. Novotny and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Paul Schaefer

93 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

2008 527 citations William F. Regine, Kathryn Winter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Schaefer United States	38	2.2k	1.2k	876	727	696	97	4.7k
Michael Lishner Israel	42	2.3k 1.0×	616 0.5×	1.2k 1.3×	650 0.9×	481 0.7×	238	6.0k
Irene Helenowski United States	39	1.7k 0.8×	967 0.8×	898 1.0×	470 0.6×	563 0.8×	232	5.7k
Lai Wei United States	38	2.2k 1.0×	852 0.7×	1.3k 1.4×	677 0.9×	511 0.7×	277	6.0k
Kathleen M. Egan United States	49	2.8k 1.2×	1.0k 0.8×	1.6k 1.8×	387 0.5×	1.1k 1.6×	159	7.8k
Jennifer Turner Australia	38	1.2k 0.5×	822 0.7×	960 1.1×	325 0.4×	362 0.5×	144	4.8k
Jianguang Ji Sweden	40	1.1k 0.5×	836 0.7×	889 1.0×	368 0.5×	455 0.7×	197	4.9k
John T. Sandlund United States	60	2.3k 1.0×	1.1k 0.9×	1.7k 2.0×	1.2k 1.6×	340 0.5×	169	10.5k
Dirk Vordermark Germany	37	1.1k 0.5×	1.2k 1.0×	1.4k 1.6×	558 0.8×	1.1k 1.6×	222	4.7k
Xiudong Lei United States	40	1.9k 0.8×	1.7k 1.4×	577 0.7×	242 0.3×	1.3k 1.8×	159	4.8k
Joellen M. Schildkraut United States	51	1.7k 0.8×	623 0.5×	2.3k 2.6×	446 0.6×	1.2k 1.7×	219	8.7k

Countries citing papers authored by Paul Schaefer

Since Specialization

Citations

This map shows the geographic impact of Paul Schaefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Schaefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Schaefer more than expected).

Fields of papers citing papers by Paul Schaefer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Schaefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Schaefer. The network helps show where Paul Schaefer may publish in the future.

Co-authorship network of co-authors of Paul Schaefer

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Schaefer. A scholar is included among the top collaborators of Paul Schaefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Schaefer. Paul Schaefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Szymanski, Kate & Paul Schaefer. (2023). Urticaria and Angioedema. Primary Care Clinics in Office Practice. 50(2). 237–252. 3 indexed citations

Brennan, Julie, et al.. (2016). A Stress Management Program for Higher Risk Medical Students: Preliminary Findings. Applied Psychophysiology and Biofeedback. 41(3). 301–305. 18 indexed citations

Ben‐Josef, Edgar, William F. Regine, Ross A. Abrams, et al.. (2015). Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas. Clinical Cancer Research. 21(24). 5612–5618. 5 indexed citations

Atherton, Pamela J., Deborah Watkins Bruner, Carolyn Gotay, et al.. (2015). The Complementary Nature of Patient-Reported Outcomes and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591). Journal of Pain and Symptom Management. 50(4). 470–479.e9. 17 indexed citations

Ng, Kimmie, Jeffrey A. Meyerhardt, Andrew T. Chan, et al.. (2014). Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. JNCI Journal of the National Cancer Institute. 107(1). 345–345. 108 indexed citations

Ogino, Shuji, Kaori Shima, Jeffrey A. Meyerhardt, et al.. (2011). Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clinical Cancer Research. 18(3). 890–900. 207 indexed citations

Govindan, Ramaswamy, Daniel Morgensztern, Roy S. Herbst, et al.. (2011). Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(4). 790–795. 16 indexed citations

Jatoi, Aminah, Shaker R. Dakhil, Jeff A. Sloan, et al.. (2010). Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Supportive Care in Cancer. 19(10). 1601–1607. 42 indexed citations

Uhm, Joon H., Karla V. Ballman, Wenting Wu, et al.. (2010). Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology*Biology*Physics. 80(2). 347–353. 134 indexed citations

10.

Jatoi, Aminah, Kendrith M. Rowland, Jeff A. Sloan, et al.. (2008). Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashes. Cancer. 113(4). 847–853. 129 indexed citations

11.

Ruggeri, Bruce, Ted L. Underiner, Diane E. Gingrich, et al.. (2007). CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models. Molecular Cancer Therapeutics. 6. 2 indexed citations

12.

Sideras, Kostandinos, et al.. (2007). Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial. Journal of Vascular Surgery. 45(4). 861–861. 12 indexed citations

13.

Schaefer, Paul, Randolph S. Marks, Michelle R. Mahoney, et al.. (2003). . American Journal of Clinical Oncology. 26(3). 236–240. 1 indexed citations

14.

Schaefer, Paul, Randolph S. Marks, Michelle R. Mahoney, et al.. (2003). Randomized Phase II Study of Daily Versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers. American Journal of Clinical Oncology. 26(3). 236–240. 9 indexed citations

15.

Dutcher, Janice P., Jason P. Fine, Robert L. Krigel, et al.. (2003). Stratification by Risk Factors Predicts Survival on the Active Treatment Arm in a Randomized Phase II Study of Interferon-Gamma Plus/Minus Interferon-Alpha in Advanced Renal Cell Carcinoma (E6890). Medical Oncology. 20(3). 271–282. 12 indexed citations

16.

Creagan, Edward T., Michael H. Veeder, Vera J. Suman, et al.. (1998). A Phase II Study of High-Dose Cimetidine and the Combination 5-Fluorouracil, Interferon Alpha-2A, and Leucovorin in Advanced Renal Cell Adenocarcinoma. American Journal of Clinical Oncology. 21(5). 475–478. 3 indexed citations

17.

Taylor, Bruce, Jan C. Buckner, Judith R. OʼFallon, et al.. (1998). Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.. Journal of Clinical Oncology. 16(6). 2195–2201. 88 indexed citations

18.

Schaefer, Paul. (1972). Infinite Matrices and Invariant Means. Proceedings of the American Mathematical Society. 36(1). 104–104. 28 indexed citations

19.

Schaefer, Paul. (1969). Almost Convergent and Almost Summable Sequences. Proceedings of the American Mathematical Society. 20(1). 51–51. 5 indexed citations

20.

Schaefer, Paul. (1969). Almost convergent and almost summable sequences. Proceedings of the American Mathematical Society. 20(1). 51–54. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact